Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2023-04-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 13th meeting of the 3rd Supervisory Board of Nanjing Yaoshi Technology Co., Ltd. It includes multiple agenda items such as approval of the 2022 Annual Report, 2022 Annual Financial Statements, 2022 Audit Report, 2022 Fundraising Use Report, 2022 Supervisory Board Work Report, 2022 Internal Control Self-Evaluation Report, 2022 Profit Distribution Plan, amendments to company policies, 2023 Q1 Report, financing proposals, and ESG report. The document repeatedly states that the reports and documents are available on the official disclosure website and that the Supervisory Board has reviewed and approved them to be submitted to the shareholders' meeting. The document itself does not contain the full annual report or financial statements but is a formal announcement of the Supervisory Board's resolutions regarding these reports and proposals. The document length is about 5988 characters, which is relatively short for a full annual report but appropriate for a meeting resolution announcement. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is an official announcement of supervisory board meeting resolutions and approvals related to various reports and proposals, not the reports themselves.
2023-04-21 Chinese
2022年度独立董事述职报告（WEIZHENG XU）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report." It details the independent director's attendance at board meetings, opinions on various board matters, committee work, investigations, and efforts to protect investor rights during the year 2022. The content focuses on the independent director's duties and activities rather than financial results or audit opinions. It is a report by a board member about their management and governance role and activities over the year. This fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to company board or senior management activities. The document is not an annual report, audit report, or earnings release, nor is it a regulatory filing or announcement. The length and detail confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2023-04-21 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度对外担保额度预计的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the estimated external guarantee amount for the year 2023 by Nanjing Yaoshi Technology Co., Ltd. It includes financial data, guarantee scope, board and independent director opinions, and compliance with regulatory requirements. The document is not a full annual report or financial statement but a specific regulatory and compliance opinion related to external guarantees. It is not a brief announcement or a certification letter but a substantive report on a particular financial regulatory matter. This fits best under Regulatory Filings (RNS) as it is a compliance-related verification document that does not fit other specific categories like Annual Report or Audit Report.
2023-04-21 Chinese
2022年度独立董事述职报告（金力）
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度独立董事述职报告" which translates to "2022 Annual Independent Director's Work Report". It is a detailed report by an independent director about their attendance, opinions, committee work, and other activities during the year 2022. The content focuses on governance, board activities, and compliance with laws and regulations. It does not contain financial statements or audit results, nor is it an announcement or a brief summary. It is a management-related report focusing on board and director activities. Therefore, it fits best under Board/Management Information (MANG). The document length is 3848 characters, which is sufficient for a detailed report but not a full annual report or audit report. Hence, the classification is MANG with high confidence.
2023-04-21 Chinese
关于公司部分募投项目延期公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the delay of certain investment projects funded by proceeds from a 2020 private placement of shares. It details the original and revised expected completion dates, reasons for the delay, and confirms that the changes do not affect the investment scope or harm shareholders. The document includes board and supervisory committee approvals and independent opinions. It is a regulatory announcement about the status of capital projects and fundraising usage, not a full financial report or earnings release. The document length is 3367 characters, which is relatively short and focused on a specific update about capital project delays. This fits best under Capital/Financing Update (CAP) as it relates to the use and timing of raised funds and project progress, rather than a full annual or interim report or other categories.
2023-04-21 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the use of temporarily idle raised funds and own funds by a listed company for cash management. It includes specifics about fundraising approvals, investment projects, risk analysis, and internal approvals. It is not a full financial report but rather a regulatory compliance and verification document related to fundraising and fund usage. The document length is 4064 characters, which is relatively short and focused on a specific topic. It does not contain comprehensive financial statements or management discussion typical of Annual Reports or Interim Reports. It is not an announcement of a report publication but a formal verification opinion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such compliance and verification documents that do not fit other specific categories.
2023-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.